Efficacy & Safety of rAd-IFN Administered With Celecoxib & Gemcitabine in Patients With Malignant Pleural Mesothelioma
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Daniel Sterman, MD
NYU Langone Laura and Isaac Perlmutter Cancer Center
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
29 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Chris O'Brien Lifehouse
Camperdown, New South Wales, Australia
- Monash Medical Centre
Clayton, Victoria, Australia
- Institut Universitaire de Cardiologie Et de Pneumologie de Quebec
Québec, Sainte-Foy, Canada
- Institut Bergonie
Bordeaux, France
- Chru de Brest - Hopital Augustin Morvan
Brest, France
- Chu de Caen - Hopital Cote de Nacre
Caen, France
- Chru de Lille
Lille, France
- Institut Curie - Oncologie Medicale
Paris, France
- Centre Hospitalier Lyon Sud
Pierre-Bénite, France
- Chu de Nantes - Hôpital Nord Laennec
Saint-Herblain, France
- Evangelisches Krankenhaus Hamm
Hamm, Germany
- Universitatsklinikum Regensburg
Regensburg, Germany
- Azienda Ospedaliero Universitaria Senese, Cancer Immunotherapy
Siena, Tuscany, Italy
- Med Polonia Sp. Z O.O.
Poznan, Poland
- Centrum Onkologii Instytut Im. Marii Sklodowskiej - Curie, Klinika Nowotworow Tkanek Miekkich, Kosci I Czerniakow
Warsaw, Poland
- Petrov National Medical Research Center of Oncology
Saint Petersburg, Russia
- Volgograd Regional Clinical Oncology Dispensary
Volgograd, Russia
- Derriford Hospital ; Derriford Hospital
Plymouth, Devon, United Kingdom
- Churchill Hospital
Oxford, Oxford, United Kingdom
- Beatson, West of Scotland Cancer Centre
Glasgow, Scotland, United Kingdom
- Royal Marsden Foundation Trust
Sutton, Surrey, United Kingdom
- Guy'S and St. Thomas' Nhs Trust
London, United Kingdom
- University of California, Los Angeles (ucla) - Medical Center
Los Angeles, California, United States
- University of California, San Francisco (ucsf)
San Francisco, California, United States
- H. Lee Moffitt Cancer Center & Research Institute
Tampa, Florida, United States
- Marlene & Stewart Greenbaum Comprehensive Cancer Center
Baltimore, Maryland, United States
- University of Maryland Medical Center
Baltimore, Maryland, United States
- Masonic Cancer Center - University of Minnesota
Minneapolis, Minnesota, United States
- University of Pennsylvania Abramson Cancer Center
Philadelphia, Pennsylvania, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 21 Jan 2019
- Primary completion
- 29 Mar 2024
- Completion
- 16 Jan 2026
- Last update posted
- 21 Apr 2026
- Registered enrollment
- 53
- Registry id
- NCT03710876
Cross-registrations
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.